Kevin Liaw
Overview
Explore the profile of Kevin Liaw including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
429
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Helble M, Zhu X, Bhojnagarwala P, Liaw K, Gao Y, Kim A, et al.
Front Immunol
. 2025 Feb;
16:1535261.
PMID: 39958352
Oncogenic forms of HPV account for 4.5% of the global cancer burden worldwide. This includes cervical, vaginal, vulvar, penile, and anal cancers, as well as head and neck cancers. As...
2.
Park D, Bhojnagarwala P, Liaw K, Bordoloi D, Tursi N, Zhao S, et al.
J Immunother Cancer
. 2024 Dec;
12(12.
PMID: 39622583
Background: Glioblastoma multiforme (GBM) is known for its high antigenic heterogeneity, which undermines the effectiveness of monospecific immunotherapies. Multivalent immunotherapeutic strategies that target multiple tumor antigens simultaneously could enhance clinical...
3.
OConnell R, Liaw K, Wellhausen N, Chuckran C, Bhojnagarwala P, Bordoloi D, et al.
J Immunother Cancer
. 2024 Jun;
12(6).
PMID: 38834201
Background: Advanced clear cell renal cell carcinoma (ccRCC) is a prevalent kidney cancer for which long-term survival rates are abysmal, though immunotherapies are showing potential. Not yet clinically vetted are...
4.
Park D, Liaw K, Bhojnagarwala P, Zhu X, Choi J, Ali A, et al.
Mol Ther Oncolytics
. 2023 Mar;
28:249-263.
PMID: 36915911
Glioblastoma multiforme (GBM) is among the most difficult cancers to treat with a 5-year survival rate less than 5%. An immunotherapeutic vaccine approach targeting GBM-specific antigen, EGFRvIII, previously demonstrated important...
5.
Tursi N, Xu Z, Helble M, Walker S, Liaw K, Chokkalingam N, et al.
Front Immunol
. 2023 Mar;
14:1072810.
PMID: 36911698
Cancer immunotherapy has demonstrated great promise with several checkpoint inhibitors being approved as the first-line therapy for some types of cancer, and new engineered cytokines such as Neo2/15 now being...
6.
Bordoloi D, Bhojnagarwala P, Perales-Puchalt A, Kulkarni A, Zhu X, Liaw K, et al.
JCI Insight
. 2022 Dec;
7(22).
PMID: 36509287
Despite advances in ovarian cancer (OC) therapy, recurrent OC remains a poor-prognosis disease. Because of the close interaction between OC cells and the tumor microenvironment (TME), it is important to...
7.
Bhojnagarwala P, OConnell R, Park D, Liaw K, Ali A, Bordoloi D, et al.
Mol Ther Oncolytics
. 2022 Sep;
26:289-301.
PMID: 36090479
Glioblastoma is an aggressive tumor with poor survival rates. Bispecific T cell engagers (BTEs) against different cancers are in various stages of clinical development. Toxicity resulting from cytokine release syndrome...
8.
Konrath K, Liaw K, Wu Y, Zhu X, Walker S, Xu Z, et al.
Cell Rep
. 2022 Jan;
38(5):110318.
PMID: 35090597
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may target epitopes that reduce durability or increase the potential for escape from vaccine-induced immunity. Using synthetic vaccinology, we have developed rationally...
9.
Kraynyak K, Blackwood E, Agnes J, Tebas P, Giffear M, Amante D, et al.
J Infect Dis
. 2022 Jan;
225(11):1923-1932.
PMID: 35079784
Background: Additional severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines that are safe and effective as primary vaccines and boosters remain urgently needed to combat the coronavirus disease 2019 (COVID-19)...
10.
Zhu X, Perales-Puchalt A, Wojtak K, Xu Z, Yun K, Bhojnagarwala P, et al.
Mol Ther Oncolytics
. 2022 Jan;
24:218-229.
PMID: 35071745
Latent Epstein-Barr virus (EBV) infection is associated with several types of cancer. Several clinical studies have targeted EBV antigens as immune therapeutic targets with limited efficacy of EBV malignancies, suggesting...